Skip to content

Press Releases and Events

PRESS RELEASES AND EVENTS

Events

There are currently no events to display.

Archived Events

Press Releases

Date Title and Summary View
Toggle Summary Intra-Cellular Therapies Announces Presentation of Lumateperone Long-term Open Label Safety Study at the 2019 Congress of the Schizophrenia International Research Society
NEW YORK , April 09, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced plans to present analyses from its open-label safety switching study (Study
View HTML
Toggle Summary Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs
NEW YORK , March 26, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of John A. Bardi as Senior Vice President for Market
View HTML
Toggle Summary Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference
NEW YORK , March 05, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
View HTML
Toggle Summary Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
NEW YORK , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31,
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference
NEW YORK , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
View HTML
Toggle Summary Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast
NEW YORK , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference
NEW YORK , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
View HTML
Toggle Summary Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease
NEW YORK , Dec. 18, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced an independent data monitoring committee (DMC) has completed a pre-specified
View HTML
Toggle Summary Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology
Favorable safety results following administration of lumateperone for up to one year treatment duration are consistent with and extend the safety and tolerability profile previously reported in short-term trials Intra-Cellular Therapies to Host a Conference Call Wednesday, December 12, 2018 at 8:30
View HTML
Toggle Summary Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia
NEW YORK , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for review
View HTML
Toggle Summary Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results
NEW YORK , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter
View HTML
Toggle Summary Intra-Cellular Therapies to Host Third Quarter 2018 Financial Results Conference Call and Webcast
NEW YORK , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
View HTML
Toggle Summary Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease
Results show ITI-214 is associated with clinical signs consistent with improvements in motor symptoms and dyskinesias               NEW YORK , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) today announced topline results from the Company’s Phase 1/2 clinical study
View HTML
Toggle Summary Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting
NEW YORK , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it will present top line results from the Company’s Phase 1/2 clinical study
View HTML
Toggle Summary Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer
NEW YORK , Oct. 16, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Mark Neumann as Executive Vice President, Chief
View HTML